A Phase 2 Multiple Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration Resistant Prostate Cancer
Study of XmAb20717 Alone or in Combination with Chemotherapy in Patients with Prostate Cancer
Sponsor: Xencor
Enrolling: Male and Female Patients
IRB Number: AAAT7510
U.S. Govt. ID: NTC05005728
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies (Olaparib, Cabazitaxel, Docetaxel, and Carboplatin). XmAb20717 has not been studied in a significant number of humans, therefore, some of its effects are unknown. XmAb20717 is an investigational antibody-drug. An antibody is a kind of protein that your body makes to help fight infections. AmAb20717 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States. The study will enroll subjects into one of 5 treatment groups based on specific information about your tumor.
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with prostate cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator